ImmunologybioRxivPreprint
Targeting activated IL-23 signaling in Scleroderma by tildrakizumab
Priyanka Verma, Roberta M Goncalves, Swarna Bale…·John Varga
This study investigates the role of IL-23 in systemic sclerosis (SSc) and shows that tildrakizumab reduces fibrosis in experimental models.
DOI 10.64898/2026.01.30.701821